Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959815 · ClinicalTrials.gov registry record
Novel Screening Strategies for Scleroderma PAH
A clinical trial of Pulmonary Arterial Hypertension and Scleroderma, sponsored by University of Michigan.
- Completed
- Registry status
- 156
- Enrollment target
- 1
- Study location
NCT01959815 is a study of Pulmonary Arterial Hypertension and Scleroderma that has completed, run by University of Michigan. The registered enrollment target is 156 participants, below the 460-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01959815, a study of Pulmonary Arterial Hypertension and Scleroderma, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with scleroderma can develop heart failure due to high blood pressure in the lungs (a condition called pulmonary arterial hypertension). It is important to find pulmonary arterial hypertension early, so that it can be treated before heart failure develops. However, the tests that we now use to find the earliest form of this disease in scleroderma patients are not good enough. This study will examine whether tests performed during exercise can improve our ability to find early pulmonary arterial hypertension. The study will also try to identify genes that are responsible for the development of pulmonary arterial hypertension.
Conditions Studied
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2013-09-26 |
| Est. Completion | 2019-11-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01959815
The ClinicalTrials.gov registry entry for NCT01959815 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 460-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (66% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT01959815 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01959815 about?
NCT01959815 is a clinical study titled "Novel Screening Strategies for Scleroderma PAH". Patients with scleroderma can develop heart failure due to high blood pressure in the lungs (a condition called pulmonary arterial hypertension). It is important to find pulmonary arterial hypertension early, so that it can be treated before heart failure develops. However, the tests that we now use...
What is the current status of trial NCT01959815?
This trial is currently completed. The enrollment target is 156 participants. The study started on 2013-09-26. Estimated completion is 2019-11-06.
What conditions does trial NCT01959815 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension, Scleroderma.
Who is sponsoring clinical trial NCT01959815?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01959815 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.